Latest Monoclonal antibodies Stories
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
MONROVIA, Calif., Nov. 4, 2014 /PRNewswire/ -- Xencor, Inc.
DALLAS, November 3, 2014 /PRNewswire/ -- According to the new market research report The "Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal
MONROVIA, Calif., Nov. 3, 2014 /PRNewswire/ -- Xencor, Inc.
Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.
More Images (1 images) »